We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vizimpro

News List

Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050 En-CPhI.CN
November 26, 2019
Pfizer Inc. announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label ...
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro instead fiercepharma
July 09, 2019
England’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer challenger.
EC approves Pfizer’s NSCLC drug Vizimpro pharmaceutical-technology
April 23, 2019
EC approves Pfizer’s NSCLC drug Vizimpro
Pfizer's once-failed Vizimpro rebounds with targeted lung cancer approval fiercepharma
September 29, 2018
After flunking two late-stage trials in 2014, Pfizer's Vizimpro won an FDA green light Thursday.
US green light for Pfizer’s lung cancer drug pharmatimes
September 29, 2018
Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.